Blue Cross Blue Shield · Rituximab Transplant · US health-plan appeal rights

Rituximab Transplant denied for failing step therapy by Blue Cross Blue Shield?

Q: How long do I have to appeal a Blue Cross Blue Shield Rituximab Transplant denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-11

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Blue Cross Blue Shield typically requires

Blue Cross Blue Shield's specific coverage criteria for rituximab transplant are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: BCBS Rituximab for Antibody-Mediated Rejection / Desensitization (Off-Label Transplant)

The Blue Cross Blue Shield angle on Rituximab Transplant

## Why BCBS Applies Step Therapy to Rituximab (Transplant)

Blue Cross Blue Shield's step-therapy (also called "fail-first") requirements for rituximab in transplant-related indications mandate that the patient try one or more other treatments before BCBS will authorize rituximab. In the transplant context, this is clinically problematic: transplant rejection and sensitization management are often time-sensitive, and the conventional step-therapy logic designed for chronic conditions may not fit the urgency or the biology of transplant medicine. BCBS medical directors applying a standard step-therapy framework to a transplant-specific protocol frequently get this wrong, making these denials highly appealable.

Many states now have step-therapy reform laws that prohibit insurers from requiring step therapy when it is clinically contraindicated, when the patient has already failed the required therapy, or when the delay would cause irreversible harm. Check your state insurance commissioner's website for applicable protections.

## Your Appeal Rights

Under ACA Section 2719, step-therapy denials are adverse benefit determinations subject to internal appeal and independent external review. Under ERISA Section 503, employer-sponsored plans must provide full-and-fair review. File an internal appeal within 180 days of the denial. If denied internally, request external review within four months of the final denial. If the situation is urgent — for example, active rejection — expedited review is available and should be requested immediately.

## Building a Strong Step-Therapy Appeal

There are typically three winning arguments against a transplant step-therapy denial: 1. The patient has already tried (and failed, or had documented adverse outcomes with) the required step agent. 2. The required step agent is clinically inappropriate in the transplant context, and a transplant specialist should explain why. 3. The time required to complete the step-therapy sequence would cause clinically unacceptable harm.

Documentation to assemble: - Complete prior treatment history with dates, agents used, doses administered, and documented outcomes — confirm with the transplant team - Prescriber letter specifically addressing each required step-therapy agent: has the patient tried it? If so, what was the outcome? If not, why is it inappropriate or contraindicated in this clinical context? - Chart documentation of clinical urgency, if applicable, supporting expedited review - BCBS's published step-therapy policy for rituximab, obtained in writing

## Criteria-Mapping Structure

Obtain BCBS's step-therapy policy for rituximab and their step-therapy exception criteria — most plans publish exception pathways for prior failure, contraindication, or clinical urgency. Map each criterion: - Step-therapy requirement: [copy the requirement verbatim] - Exception pathway claimed: [identify which exception applies: prior failure, contraindication, or urgency] - Supporting documentation: [cite specific chart records with dates that establish the exception]

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Blue Cross Blue Shield appeals

Other denial reasons for Blue Cross Blue Shield Rituximab Transplant

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-11. Editorial standards: denialhelp.com/authors.